- Report
- August 2023
- 92 Pages
Global
From €3500EUR$4,131USD£3,054GBP
- Report
- August 2023
- 106 Pages
Global
From €3500EUR$4,131USD£3,054GBP
- Report
- July 2023
- 108 Pages
Global
From €3500EUR$4,131USD£3,054GBP
- Report
- February 2022
- 84 Pages
Global
From €3200EUR$3,777USD£2,792GBP
- Report
- November 2024
- 90 Pages
Australia
From €1181EUR$1,301USD£996GBP
€1687EUR$1,859USD£1,422GBP
- Book
- January 2015
- 464 Pages
The Subunit Vaccine market is a subset of the Vaccine market, which is composed of products designed to prevent or reduce the severity of infectious diseases. Subunit vaccines are made from antigens, which are parts of a virus or bacteria that stimulate an immune response. These vaccines are typically safer than traditional vaccines, as they do not contain the entire virus or bacteria, and are therefore less likely to cause adverse reactions. Subunit vaccines are also more stable than traditional vaccines, and can be stored at room temperature for longer periods of time.
Subunit vaccines are used to treat a variety of diseases, including influenza, hepatitis B, and human papillomavirus. They are also used in combination with other vaccines to provide broader protection against multiple diseases.
Some companies in the Subunit Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi, Pfizer, and Novartis. Show Less Read more